Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

What happened

Junshi Biosciences announced that final analysis results from its Phase 3 NEOTORCH study were presented at the ESMO Congress 2026 and published in Annals of Oncology. The trial tested perioperative toripalimab plus chemotherapy in 501 patients with resectable stage II-III non-small cell lung cancer.

Confirmed

Global impact / market context

Positive final results could support wider use of toripalimab in earlier-stage lung cancer, a setting where treatment before and after surgery may reach more patients. That could lift product revenue, but the article does not give the size of any financial benefit.

Analyst inference

Lung cancer is a large treatment area, so a drug showing durable benefit in earlier stages can change how doctors choose therapy. The article gives no sales figures, pricing, or competitor data, so the commercial effect on Junshi remains uncertain.

Analyst inference

What to watch

1. Watch whether Junshi discloses regulatory filing plans for perioperative toripalimab in this lung cancer setting, since approvals would be needed before broader commercial use. Confirmed
2. Watch for company revenue updates that separate toripalimab sales tied to early-stage lung cancer, which would show whether the trial result is translating into actual prescriptions. Analyst inference
3. Watch whether future disclosures include full survival and safety details beyond event-free survival, because those details shape how doctors weigh the regimen against alternatives. Analyst inference

Evidence

• globenewswire.com